Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$50 mil. to fix Stryker quality problems

This article was originally published in The Silver Sheet

Executive Summary

Stryker says it will spend at least $50 million a year "over the next few years" to resolve quality systems issues related to three FDA warning letters, Katherine Owen, the firm's VP for strategy and investor relations, said during a Sept. 3 presentation at the Thomas Weisel Partners Healthcare Conference in Boston. The company's biotech division received a letter in April citing quality system and compliance violations at its Hopkinton, Mass., facility ("The Silver Sheet" May 2008). That letter was Stryker's third since March 2007; the other two came following FDA inspections of the firm's Mahwah, N.J., and Carrigtwohill, Ireland, plants
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT036272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel